Moderna, Inc.
Customers
2
1 active
Suppliers
1
1 active
Largest customer
11%
CAH · FY to 2025-12-31
Named-customer revenue
$213.8M
1 customer · FY to 2025-12-31
Latest period
Jun 30, 2026
10-Q filed 2026-08-04
Customers 2
Companies MRNA discloses as major customers, as a share of MRNA revenue. 1 active, 1 lapsed.
| Company | % of MRNA revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| Ministry Of Health, Labor, And Welfare Of Japan Non-SEC Ministry Of Health, Labor, And Welfare Of Japan |
21% | $1.4B | FY 2023-12-31 | Lapsed Last seen 2023-12-31 |
10-K 2026-02-20 | |
Ministry of Health, Labor, and Welfare of Japan * * 21 % * * | ||||||
| CAH Distributor CARDINAL HEALTH INC |
11% | $213.8M | FY 2025-12-31 | Active | 10-K 2026-02-20 | |
Cardinal Health 11 % * * * * | ||||||
Suppliers 1
Companies that disclose MRNA as a major customer, as a share of their own revenue. 1 active, 0 lapsed.
| Company | % of their revenue | Est. $ from MRNA | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| PSNL Personalis, Inc. |
12% | $2.7M | 3M 2026-06-30 | −4.0pp | Active | 10-Q 2026-08-04 |
Multiple customers have provided more than 10% of total revenue in the periods presented, or accounted for more than 10% of accounts receivable at each respective balance sheet date, as follows: Revenue Accounts Receivable Three Months Ended June 30, Six Months Ended June 30, June 30, 2026 December 31, 2025 2026 2025 2026 2025 Merck & Co., Inc. (1) 37% 11% 30% * 49% 12% VA MVP 13% 19% 15% 20% * * ModernaTX, Inc. 12% 29% 14% 28% * * Natera, Inc. * 13% * 13% * * US Department of Veterans Affairs * * * * * 24% AstraZeneca UK Limited * * * * * 10% * Less than 10% of revenue or accounts receivable.(1) Consists of related party revenue and related party accounts receivable, respectively. Multiple customers have provided more than 10% of total revenue in the periods presented, or accounted for more than 10% of accounts receivable at each respective balance sheet date, as follows: Revenue Accounts Receivable Three Months Ended March 31, March 31, 2026 December 31, 2025 2026 2025 Merck & Co., Inc. (1) 19% * 33% 12% VA MVP 16% 20% * * Moderna, Inc. 16% 27% 14% * Natera, Inc. * 12% * * Genentech, Inc. * * 22% * US Department of Veterans Affairs * * * 24% AstraZeneca UK Ltd * * * 10% * Less than 10% of revenue or accounts receivable (1) Consists of related party revenue and related party receivable, respectively. Moderna accounted for 22% and 28% and the VA MVP accounted for 17% and 9% of our revenue for the years ended December 31, 2025 and 2024, respectively. Multiple customers have provided more than 10% of total revenue in the periods presented, or accounted for more than 10% of accounts receivable at each respective balance sheet date, as follows: Revenue Accounts Receivable Three Months Ended September 30, Nine Months Ended September 30, September 30, 2025 December 31, 2024 2025 2024 2025 2024 ModernaTX, Inc. 19% 33% 25% 28% 11% * Regeneron Pharmaceuticals 19% * * * 19% * Pfizer Inc. 11% * * * 12% 25% Natera, Inc. * 20% 10% 31% * 13% Merck & Co., Inc. * * * * 18% 31% VA MVP * 17% 15% 11% * * * Less than 10% of revenue or accounts receivable.Significant Accounting PoliciesAs of September 30, 2025, the Company’s significant accounting policies are consistent with those discussed in Note 2 - “Summary of Significant Accounting Policies” in its consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. | ||||||
Alerts are coming
Get an email when MRNA's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.